Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Repligen ( (RGEN) ) has provided an update.
On January 6, 2026, Repligen Corporation announced that its board has elected independent director Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, succeeding Executive Chair Tony Hunt, who will retire from the board on that date after more than a decade of leadership and will remain an advisor to the company through March 2027. The transition underscores Repligen’s effort to maintain strong governance and continuity in its bioprocessing-focused strategy, with management highlighting Madaus’s 36 years of industry experience—including his tenure leading Millipore’s transformation into a life sciences leader—as a key asset expected to support Repligen’s next phase of growth while reassuring stakeholders about stability in its leadership and long-term direction.
The most recent analyst rating on (RGEN) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.
Spark’s Take on RGEN Stock
According to Spark, TipRanks’ AI Analyst, RGEN is a Neutral.
Repligen’s overall stock score reflects strong earnings call performance and positive technical indicators, tempered by high valuation concerns. The company’s financial performance is stable, with opportunities for improvement in profitability. The positive sentiment from the earnings call and technical momentum are significant strengths, while the high P/E ratio is a notable risk.
To see Spark’s full report on RGEN stock, click here.
More about Repligen
Repligen Corporation is a global life sciences company specializing in bioprocessing technologies and systems that improve the efficiency of manufacturing biological drugs. The company serves biopharmaceutical drug developers and contract development and manufacturing organizations worldwide, with focus areas spanning Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Headquartered in Waltham, Massachusetts, Repligen operates most of its manufacturing sites in the U.S., with additional key facilities in Estonia, France, Germany, Ireland, the Netherlands and Sweden.
Average Trading Volume: 826,372
Technical Sentiment Signal: Buy
Current Market Cap: $9.54B
Find detailed analytics on RGEN stock on TipRanks’ Stock Analysis page.